Geneseq Biosciences, Melbourne, Australia.
PLoS One. 2019 Feb 5;14(2):e0211504. doi: 10.1371/journal.pone.0211504. eCollection 2019.
Histopathologic examination of melanocytic neoplasms can be challenging and subjective, with no specific circulating or tissue-based biomarkers currently available. Recently, a circulating 38-microRNA profile of melanoma (Mel38) was described. In this study, Mel38 expression and its impact on downstream mRNA regulation in solid tissue is examined.
Mel38 was applied to archival, clinically-annotated, solid-tissue genomic datasets representing benign naevi, primary and metastatic melanoma. Statistical analysis of the signature in relation to disease status, patient outcome and molecular pathways was performed.
Mel38 is able to stratify genomic data from solid tissue biopsies on the basis of disease status and differences in melanoma-specific survival. Experimentally-verified messenger-RNA targets of Mel38 also exhibit prognostic expression patterns and represent key molecular pathways and events in melanoma development and progression.
The Mel38 microRNA profile may have diagnostic and prognostic utility in solid tissue as well as being a robust circulating biomarker of melanoma.
黑素细胞肿瘤的组织病理学检查具有挑战性且主观性强，目前尚无特异性的循环或组织生物标志物。最近，描述了一种循环黑素瘤 38 个 microRNA 特征（Mel38）。在这项研究中，研究了 Mel38 在实体组织中的表达及其对下游 mRNA 调控的影响。
将 Mel38 应用于代表良性痣、原发性和转移性黑素瘤的存档、临床注释的实体组织基因组数据集。对该特征与疾病状态、患者预后和分子途径的关系进行了统计分析。
Mel38 能够根据疾病状态和黑素瘤特异性生存的差异对来自实体组织活检的基因组数据进行分层。Mel38 的实验验证信使 RNA 靶标也表现出预后表达模式，代表了黑色素瘤发生和进展中的关键分子途径和事件。
Mel38 microRNA 谱在实体组织中可能具有诊断和预后效用，并且是黑素瘤的一种稳健的循环生物标志物。
